Itron shares came into this print with a flat three month return and just a modest gain over the past month. Then Q3 2026 landed and the stock jumped 7.8% to US$94.55 as traders reacted to a clean earnings beat.
The real story sits in profitability. Management turned US$599.3 million of quarterly revenue into US$71.4 million of net income and record non GAAP earnings power, a step up that matters far more for long term holders than today's pop alone.
Impressed by Itron's earnings beat and profit conversion but looking for a shortlist of companies that combine solid fundamentals with resilient balance sheets? Consider this curated screener: list of solid balance sheet and fundamentals stocks (24 results)
Q3 2026 Earnings Summary
-
Revenue (Q3 2026 vs. Q3 2025):US$599.3 million vs. US$581.6 million (up about 3%)
-
Net Income (Excl. Extra Items, Q3 2026 vs. Q3 2025):US$71.4 million vs. US$65.6 million (up about 9%)
-
Basic EPS (Q3 2026 vs. Q3 2025):US$1.63 vs. US$1.43 (up about 14%)
-
Trailing Net Profit Margin (Last 12 Months vs. Prior Year):12.1% vs. 10.7% (margin level higher year on year)
Earnings paint one picture for Itron, but cash generation often tells you more about what you are actually paying for the business. If you look at Itron's cash flows rather than just the latest EPS line, the stock could be a meaningful 25% undervalued .
Itron bull story: backlog and software mix on trial
Supporters argue that Itron's long term edge rests on deepening its role as the intelligence layer and scaling recurring software and services.
"Ongoing industry wide digitalization and utility interest in grid edge intelligence, seen in expanding deployments of distributed intelligence enabled endpoints and recent launches such as Itron Riva IEC meters and IEE Cloud AI, supports further adoption of Outcomes offerings and can lift recurring software and services revenue as a share of total revenue."
Q3 gives that view real footing. Grid Edge Intelligence endpoints reached more than 19.4 million, ARR hit about US$423 million and Outcomes plus Resiliency Solutions now exceed 25% of backlog. Record 41.3% adjusted gross margin and quarterly high adjusted EBITDA of US$115 million show the higher margin mix is flowing through.
Itron bear story: project timing and margin durability checked
Skeptics worry that slow moving utility programs and mix driven margins could unwind the recent earnings progress.
"Customers and regulators are slowing project deployments and delaying decisions due to increased capital budget pressures, affordability concerns and regulatory scrutiny, and this is visible in Itron reporting that certain large Networked Solutions programs have been spread over longer time frames and that full year 2025 revenue fell 3% versus 2024 after the catch up period ended, which could continue to restrain revenue growth and keep earnings sensitive to deployment timing."
Q3 results soften that concern but do not erase it. Revenue landed at US$599 million, right at the top of outlook, while bookings grew 27% and backlog reached US$4.3b, aided by Networked Solutions. Yet management still flags lumpy bookings and regulatory timing, so the deployment risk remains live even as raised 2026 EPS guidance and a 7.8% share price jump show investors rewarding current execution.
One Narrative has put a figure on that disagreement. → See the Narrative with its higher Fair Value, assumptions and all .
Hunt For Quiet Fundamental Shifts
Itron just showed how a single quarter can reset expectations for a complex business. The real opportunity could be spotting solid companies that look mispriced before the crowd closes the gap.
-
Company 1 - 15% below our estimate - uses specialty contractors to capture hyperscale data center buildouts, while rising working capital and concentrated ownership reshape the risk profile.
-
Company 2 - 27% below our estimate - turns grid modernization, aerospace programs and diagnostic test demand into higher margin engineered systems as a new acquisition gets integrated.
-
Company 3 - 23% below our estimate - expands surgical robotics and Smart Care offerings into more procedures while reworking factories and supply chains to support higher margin medical equipment.
Three companies from the same screener. Open all 29 potentially undervalued companies →
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ITRI .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
